DigestRedComo funciona
Red
/
Empresas
Pr
No verificado

Prilenia Therapeutics B.V.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
10/10/2025
Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
06/10/2025
Multimedia
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Industria
Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
05/09/2025
Multimedia
Biotecnología
Farmacéutica
Libros/Industria editorial
Sanidad
Salud
Comunicación
Medicina - Varios
Análisis de Mercados
Industria
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
25/07/2025
Multimedia
Salud
Ciencia
Farmacéutica
Biotecnología
Industria
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
28/04/2025
Mercado laboral
Industria
Salud
Ciencia
Farmacéutica
Biotecnología
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
05/11/2024
Eventos
Industria
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 Congress
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
19/09/2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
03/09/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0